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RegioselectivityAn efﬁcient method for the regioselective synthesis of potentially biologically active tetrasubstituted 1-
pyrazolines has been achieved via a 1,3-dipolar cycloaddition reaction. A range of tetrasubstituted 1-pyr-
azolines bearing one Boc group and two ester groups were obtained in high yields (up to 99%). The struc-
ture and relative stereochemistry of cycloadducts were conﬁrmed by NMR spectra and single crystal X-
ray diffraction. The possible mechanism was proposed and the major Z-cycloadducts as a single diaste-
reomer could be separated from each other by chromatography.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.Pyrazolines are heterocyclic compounds of ﬁve membered
unsaturated ring structure composed of three carbon atoms and
two nitrogen atoms in adjacent positions. These nitrogen heterocy-
cles and their derivatives are versatile synthetic blocks, frequent
structural skeleton of natural products, or potential drug mole-
cules.1 Many of them showed a broad spectrum of biological activ-
ities such as analgesic,2 anti-inﬂammatory,3 antipyretic,4
antiarrhythmic,4 antidepressant,5 anticonvulsant,6 antioxidant,7
antihypertensive,8 antidiabetic,4,9 antimicrobial,10 and anticancer
activities.11 In addition, these heterocycles were also widely used
as dyestuffs,12 analytical reagents,13 and agrochemicals.14 Because
of these diverse properties, synthesis of pyrazolines and pyrazoline
derivatives has been a developing ﬁeld within the realm of hetero-
cyclic chemistry. Currently, a variety of synthetic methods for the
preparation of these compounds were reported. In general, the
synthesis of pyrazolines by the so-called [3+2] atom fragments
has been relatively well investigated. In this method, b-diketones
or their derivatives (the three-atom fragment) are condensed with
hydrazine or its derivatives (the two-atom fragment) to close a
ﬁve-membered ring.12,13,15,16 The second strategy is the classical1,3-dipolar cycloaddition (1,3-DC) reaction of diazoalkanes or ni-
trile imines, and the usual dipolarophiles for this purpose are al-
kynes,17 alkyne equivalents,18 or alkenes.19 Despite these
successes, the design and synthesis of new complex pyrazoline
derivatives possessing biological activities are still a challenge
and have become a much attempted research endeavor. So far,
the synthesis of functionalized 2-pyrazoline by 1,3-DC reactions
between nitrile imines and alkene has been extensive investi-
gated.19,20 However, only a few references for preparation of poly-
substituted 1-pyrazoline by the 1,3-DC reaction were found.21 To
the best of our knowledge, the Baylis–Hillman adduct is a struc-
tural motif and is often found in bioactive molecules. The use of
such oleﬁn as dipolarophiles in 1,3-DC reaction for the production
of new pyrazoline derivatives with biological interest is not very
extensive. As a part of our own interest in cycloaddition reactions,
we report herein the efﬁcient synthesis of novel tetrasubstituted 1-
pyrazolines via 1,3-dipolar cycloaddition of Baylis–Hillman ad-
ducts and acyl diazomethanes.
Initially, we chose methyl a-benzyl-a-diazoacetate 1a and the
Baylis–Hillman adduct derived from 4-nitrobenzaldehyde 2a as
model substrates for establishing the feasibility of the strategy
and the optimal reaction conditions. A variety of Lewis bases were
ﬁrst screened as catalysts for the reaction. After the mixture of 1a
(0.1 mmol), 2a (0.1 mmol) and catalyst (20 mol %, such as DABCO,
Ph3P, Et3N, and DBU) in dichloromethane (1.0 mL) being stirred at
25 C for 24 h, tetrasubstituted 1-pyrazoline 3a was obtained in a
low yield (Table 1, entries 1–4). However, in another parallel
experiment, a blank reaction without a catalyst gave the desired
Table 1
Optimization of reaction conditions to yield compound 3aa
Entry Catalyst Solvent Temp (C) Yieldb (%)
1 DABCO CH2Cl2 25 32
2 Ph3P CH2Cl2 25 Trace
3 Et3N CH2Cl2 25 35
4 DBU CH2Cl2 25 13
5 — CH2Cl2 25 38
6 — THF 25 54
7 — Toluene 25 47
8 — CH3CN 25 52
9 — CHCl3 25 51
10 — CH3OH 25 75
11 — EtOH 25 66
12 — n-PrOH 25 78
13 — i-PrOH 25 89
14 — n-BuOH 25 66
15 — i-BuOH 25 58
16 — i-PrOH 35 99
17 — i-PrOH 65 98
18 — i-PrOH 20 Trace
a The reaction was carried out in 0.1 mmol scale in solvent (1.0 mL) at 25 C for
24 h, and the ratio of 1a/2a/catalyst is 1:1:0.2.
b Isolated yield based on Baylis–Hillman adduct.
H. Sun et al. / Tetrahedron Letters 54 (2013) 3846–3850 3847product with equivalent yield (Table 1, entry 5). This result indi-
cated that catalyst may not play a role, even led to a lower reaction
activity. Considering the easy nature of the above process, the reac-
tion will not need the catalyst.
The structure of cycloadduct 3a was conﬁrmed through
spectroscopic analysis. We were pleased to see that the reaction
afforded the adduct 3a as a single regioisomer (Scheme 1). As
shown in Scheme 1, from the resonance structure B, C, D of the dia-
zo group it is obvious that the carbon, to which the diazo group is
attached, has a partial negative charge. Electrophiles usually attack
at the carbon atom, while the terminal nitrogen of the diazo group
is attacked by nucleophiles. Therefore, 3a was exclusively formed
according to the regulations obtained from previous reports on
the 1,3-dipolar addition of acyl diazomethanes with alkenes.21b–d
Next, the diastereoselectivity of the reaction and relative conﬁg-
urations of the stereogenic centers of the cycloadduct 3a were also
determined by NMR spectra and single crystal X-ray analysis.
Based on the chemical shifts and coupling constants of the ali-
phatic protons in proton NMR (Fig. 1), the adduct 3a is a mixture

































Scheme 1. 1,3-Dipolar cycloaddition reaction for synthesis of tetrasubstituted 1-
pyrazoline 3a.1a cycloaddition to the Baylis–Hillman adduct 2a is completely
regioselective but yielded a mixture of diastereomers (3aa, 3ab,
and 3ac). The exact ratio of diastereomers has been determined
by comparing the integral values of aliphatic protons in crude reac-
tion mixture, especially, methoxyl protons (diastereoselectivity
66:26:8). Only 3aa as a single diastereomer could be separated
from each other by chromatography and the rest of cycloadducts
(3ab, 3ac) yielded an inseparable diastereomeric mixture. In Fig-
ure 1, the proton NMR spectra of 3aa, 3ab, and 3ac indicating
the aliphatic and methoxyl protons are shown. Among the ali-
phatic protons, Ha is the most deshielded one due to its proximity
to oxygen and the phenyl moiety and it appeared at around
6.4 ppm in three isomers as a singlet. The methylene protons of
the benzyl (Hb and Hc) in three isomers resonated relatively up
ﬁeld (3.14–3.52 ppm) with a J = 14.0 Hz. The methylene protons
of the pyrazoline ring (Hd and He) exhibited AB doublets at d
2.60 and at d 1.72 ppm (J = 13.6 Hz). In addition, the HMBC spectra
conﬁrmed that the connectivities of these protons to the carbons
were in accord with the assigned structures. The stereochemical
outcome of the cycloaddition was determined by single crystal
X-ray analysis of the cycloadduct 3aa (Fig. 2).22 The X-ray structure
of the product 3aa reﬂects that the cycloaddition proceeds via two
models (Scheme 2).
To improve the yield, efforts were made to optimize other reac-
tion parameters including solvents and reaction temperatures. Dif-
ferent solvents including THF, toluene, CH3CN, CHCl3, CH3OH, and
EtOHwere investigated and the results are listed in Table 1 (entries
6–11). To our delight, the reaction in methanol led to the desired
product in a yield of 75% (Table 1, entry 10), while ethanol as sol-
vent gave the product in only 66% yield (Table 1, entry 11). In gen-
eral, reactions carried out in protic solvents were better yielding
than those in aprotic solvents. Further improvement was achieved
by employing i-PrOH as solvent and the tetrasubstituted 1-pyraz-
oline 3a was obtained in 89% yield (Table 1, entry 13).
Temperature inﬂuenced the rate of the reaction, but had no
obvious effect on the diastereoselectivity. Reducing the reaction
temperature resulted in a low reactivity (Table 1, entry 18), while
conducting the reaction at 35 C provided the best results (Table 1,
entry 16). Based on the comprehensive consideration of reaction
temperature and yield, the optimal reaction conditions were estab-
lished as shown in Table 1, entry 16. The ratio of three diastereo-
mers remained the same in all the cases.
Having the optimized conditions in hand, the scope of Baylis–
Hillman adducts was examined by using methyl a-benzyl-a-diazo-
acetate 1a as 1,3-dipole. The results are shown in Table 2. Although
the diastereoselectivities of these reactions were low, it did not ef-
fect on the formation of products in higher yields during the course
of reaction. A variety of Baylis–Hillman adducts proved to be excel-
lent dipolarophiles for this reaction, and provided the correspond-
ing tetrasubstituted 1-pyrazolines in good yields (up to 99%).
Substituents on aryl groups inﬂuenced slightly the yields. (Table 2,
entries 1–10). Generally, Baylis–Hillman adducts derived from 4-
substituted benzaldehyde gave higher yields than those derived
from 2-substituted and 3-substituted benzaldehyde. Baylis–Hill-
man adducts with electron-donating groups and with
electron-withdrawing groups all gave good yields. However, the
diastereoselectivities of the reaction were affected by the position
of substituents at the aromatic ring. The 2-Br substituted Baylis–
Hillman adduct yielded four diastereomers (diastereoselectivity
25:25:25:25) (Table 2, entry 10) and the diastereomers could not
be separated. Naphthyl and heterocyclic substituents participated
in smooth cycloaddition reactions in 97% and 89% yield, respectively
(Table 2, entries 11, 12). It isworthwhile to note that the Baylis–Hill-
man adduct derived from cinnamaldehyde was examined and was
transformed with a yield of 81% (Table 2, entry 13). Moreover,












































Figure 1. Proton NMR splittings of the diastereomers 3aa, 3ab, and 3ac.




































Scheme 2. Proposed models for cycloaddition.
3848 H. Sun et al. / Tetrahedron Letters 54 (2013) 3846–3850the ethyl ester group, the reaction still proceeded smoothly to
generate tetrasubstituted 1-pyrazoline in almost quantitative yield
(99%) (Table 2, entry 14). To our satisfaction,when the aliphatic Bay-
lis–Hillman adduct was the substrate, the desired product was
obtained in 91% yield (Table 2, entry 15). The stereochemistry of
the other products was assigned by analogy to the relative conﬁgu-
ration of 3aa.
In conclusion, we have developed an efﬁcient method for the
regioselective synthesis of potentially biologically active tetrasub-stituted 1-pyrazolines via a 1,3-dipolar cycloaddition reaction. A
range of tetrasubstituted 1-pyrazolines bearing one Boc group
and two ester groups were obtained in high yields (up to 99%).
The reaction is simple, easy availability of starting materials, con-
venient with mild reaction conditions, and the diastereomers of
the product can be separated with simple puriﬁcation, which make
it a useful and attractive process for the preparation of novel pyr-
azoline derivatives. The structures and relative stereochemistry of
products were assigned by NMR and single crystal X-ray data.
Transformation of these partially unsaturated cycloadducts to fully
aromatized pyrazoles is currently under investigation in our
Table 2





























Entry R1 R2 3 Yieldb (%) Diastereomeric ratioc
1 4-NO2Ph Me 3a 99 66:26:8 (s)
2 4-CNPh Me 3b 99 63:24:13 (s)
3 4-FPh Me 3c 99 50:30:20 (s)
4 4-ClPh Me 3d 90 62:19:19 (s)
5 4-BrPh Me 3e 93 66:22:12 (s)
6 Ph Me 3f 99 50:34:16 (s)
7 4-CH3Ph Me 3g 99 52:32:16 (s)
8 3-CF3Ph Me 3h 90 60:28:12 (s)
9 3-CH3Ph Me 3i 96 50:34:16 (s)
10 2-BrPh Me 3j 94 25:25:25:25 (i)
11 2-Naphthyl Me 3k 97 79:11:10 (s)
12 2-Pyridinyl Me 3l 89 50:34:16 (s)
13 Me 3m 81 57:33:10 (s)
14 4-NO2Ph Et 3n 99 63:28:9 (s)
15 CH3CH2 Me 3o 91 75:19:6 (s)
a The reaction was carried out in 0.1 mmol scale in i-PrOH (1.0 mL) at 35 C for 24 h, and the ratio of 1a/2 is 1:1.
b Isolated yield based on Baylis–Hillman adduct.
c Assigned isomeric ratio using 1H NMR. i = inseparable mixture. s = separated.
H. Sun et al. / Tetrahedron Letters 54 (2013) 3846–3850 3849research group and anticipated to furnish other new pyrazoline
derivatives and pyrazole derivatives. Further study on the antibac-
terial and antitumor activities of these compounds is underway.
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